Evidence map›Paper›PMID 39145773›Full record

ArticleeLife2024

Probing PAC1 receptor activation across species with an engineered sensor.

Reto B Cola, Salome N Niethammer, Preethi Rajamannar, Andrea Gresch, Musadiq A Bhat, Kevin Assoumou, Elyse T Williams, Patrick Hauck, Nina Hartrampf, Dietmar Benke and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Reto B ColaInstitute of Pharmacology and Toxicology, University of Zürich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-1419-2480
Salome N NiethammerMedical University of Vienna, Center for Brain Research, Department for Neuronal Cell Biology, Vienna, Austria.
Preethi RajamannarDepartment of Molecular Neuroscience & Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Andrea GreschInstitute of Pharmacology and Toxicology, University of Zürich, Zurich, Switzerland.
Musadiq A BhatInstitute of Pharmacology and Toxicology, University of Zürich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-0894-9996
Kevin AssoumouDepartment of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland.
Elyse T WilliamsDepartment of Chemistry, University of Zürich, Zürich, Switzerland.
Patrick HauckDepartment of Chemistry, University of Zürich, Zürich, Switzerland.
Nina HartrampfDepartment of Chemistry, University of Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0003-0875-6390
Dietmar BenkeInstitute of Pharmacology and Toxicology, University of Zürich, Zurich, Switzerland.
Miriam StoeberDepartment of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-5210-2864
Gil LevkowitzDepartment of Molecular Neuroscience & Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID https://orcid.org/0000-0002-3896-1881
Sarah MelzerMedical University of Vienna, Center for Brain Research, Department for Neuronal Cell Biology, Vienna, Austria.ORCID https://orcid.org/0000-0001-6028-9764
Tommaso PatriarchiInstitute of Pharmacology and Toxicology, University of Zürich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-9351-3734

Funding

City of Vienna VRG21-015European Research Council 891959Israel Ministry of Science and Technology 3-16548Israel Science Foundation 349/21Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_196455Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030L_212508Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung PCEFP3_181282Vienna Science and Technology Fund (WWTF) 10.47379/VRG21015
6 · The paper itself

Abstract

Class-B1 G-protein-coupled receptors (GPCRs) are an important family of clinically relevant drug targets that remain difficult to investigate via high-throughput screening and in animal models. Here, we engineered PAClight1

Indexed as

ZebrafishAnimalsBiosensing TechniquesHEK293 CellsHumansLigandsMiceProtein EngineeringReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type ILigandsReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type Iadenylate cyclase-activating polypeptidebiochemistrychemical biologygenetically-encoded fluorescent sensorshumanmouseneuropeptidesPAC1 receptorPACAPvasoactive intestinal peptideVIPzebrafish

Identifiers

PMID39145773
PMCPMC11326774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.